FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978768078> ?p ?o ?g. }

• W1978768078 endingPage "1087" @default.
• W1978768078 startingPage "1075" @default.
• W1978768078 abstract "This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary tumor response of a nanoparticulate formulation of paclitaxel (Nanotax®) administered intraperitoneally for multiple treatment cycles in patients with solid tumors predominantly confined to the peritoneal cavity for whom no other curative systemic therapy treatment options were available. Twenty-one patients with peritoneal malignancies received Nanotax® in a modified dose-escalation approach utilizing an accelerated titration method. All patients enrolled had previously received chemotherapeutics and undergone surgical procedures, including 33 % with optimal debulking. Six doses (50–275 mg/m2) of Cremophor-free Nanotax® were administered intraperitoneally for one to six cycles (every 28 days). Intraperitoneal (IP) administration of Nanotax® did not lead to increases in toxicity over that typically associated with intravenous (IV) paclitaxel. No patient reported ≥Grade 2 neutropenia and/or ≥Grade 3 neurologic toxicities. Grade 3 thrombocytopenia unlikely related to study medication occurred in one patient. The peritoneal concentration–time profile of paclitaxel rose during the 2 days after dosing to peritoneal fluid concentrations 450–2900 times greater than peak plasma drug concentrations and remained elevated through the entire dose cycle. Best response assessments were made in 16/21 patients: Four patients were assessed as stable or had no response and twelve patients had increasing disease. Five of 21 patients with advanced cancers survived longer than 400 days after initiation of Nanotax® IP treatment. Compared to IV paclitaxel administration, Cremophor-free IP administration of Nanotax® provides higher and prolonged peritoneal paclitaxel levels with minimal systemic exposure and reduced toxicity." @default.
• W1978768078 created "2016-06-24" @default.
• W1978768078 creator A5002299630 @default.
• W1978768078 creator A5008466254 @default.
• W1978768078 creator A5012414525 @default.
• W1978768078 creator A5012517342 @default.
• W1978768078 creator A5015069511 @default.
• W1978768078 creator A5017381866 @default.
• W1978768078 creator A5018284120 @default.
• W1978768078 creator A5019440121 @default.
• W1978768078 creator A5025517651 @default.
• W1978768078 creator A5027304240 @default.
• W1978768078 creator A5038774956 @default.
• W1978768078 creator A5044916391 @default.
• W1978768078 creator A5071439052 @default.
• W1978768078 creator A5079842256 @default.
• W1978768078 creator A5084542258 @default.
• W1978768078 creator A5086602129 @default.
• W1978768078 creator A5087699643 @default.
• W1978768078 date "2015-04-23" @default.
• W1978768078 modified "2023-10-14" @default.
• W1978768078 title "A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies" @default.
• W1978768078 cites W1836451026 @default.
• W1978768078 cites W1871865048 @default.
• W1978768078 cites W1922469696 @default.
• W1978768078 cites W1999044622 @default.
• W1978768078 cites W2016888963 @default.
• W1978768078 cites W2022157561 @default.
• W1978768078 cites W2038163024 @default.
• W1978768078 cites W2041430550 @default.
• W1978768078 cites W2044221999 @default.
• W1978768078 cites W2057831335 @default.
• W1978768078 cites W2061842343 @default.
• W1978768078 cites W2063382894 @default.
• W1978768078 cites W2065603549 @default.
• W1978768078 cites W2076668534 @default.
• W1978768078 cites W2092196923 @default.
• W1978768078 cites W2117995467 @default.
• W1978768078 cites W2120383355 @default.
• W1978768078 cites W2124417306 @default.
• W1978768078 cites W2126077921 @default.
• W1978768078 cites W2139248078 @default.
• W1978768078 cites W2141086589 @default.
• W1978768078 cites W2142114138 @default.
• W1978768078 cites W2142504874 @default.
• W1978768078 cites W2145827555 @default.
• W1978768078 cites W2154175915 @default.
• W1978768078 cites W2213012239 @default.
• W1978768078 cites W2316501478 @default.
• W1978768078 cites W2491210927 @default.
• W1978768078 cites W4685949 @default.
• W1978768078 cites W59436246 @default.
• W1978768078 cites W9145604 @default.
• W1978768078 doi "https://doi.org/10.1007/s00280-015-2737-4" @default.
• W1978768078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4506131" @default.
• W1978768078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25898813" @default.
• W1978768078 hasPublicationYear "2015" @default.
• W1978768078 type Work @default.
• W1978768078 sameAs 1978768078 @default.
• W1978768078 citedByCount "49" @default.
• W1978768078 countsByYear W19787680782016 @default.
• W1978768078 countsByYear W19787680782017 @default.
• W1978768078 countsByYear W19787680782018 @default.
• W1978768078 countsByYear W19787680782019 @default.
• W1978768078 countsByYear W19787680782020 @default.
• W1978768078 countsByYear W19787680782021 @default.
• W1978768078 countsByYear W19787680782022 @default.
• W1978768078 countsByYear W19787680782023 @default.
• W1978768078 crossrefType "journal-article" @default.
• W1978768078 hasAuthorship W1978768078A5002299630 @default.
• W1978768078 hasAuthorship W1978768078A5008466254 @default.
• W1978768078 hasAuthorship W1978768078A5012414525 @default.
• W1978768078 hasAuthorship W1978768078A5012517342 @default.
• W1978768078 hasAuthorship W1978768078A5015069511 @default.
• W1978768078 hasAuthorship W1978768078A5017381866 @default.
• W1978768078 hasAuthorship W1978768078A5018284120 @default.
• W1978768078 hasAuthorship W1978768078A5019440121 @default.
• W1978768078 hasAuthorship W1978768078A5025517651 @default.
• W1978768078 hasAuthorship W1978768078A5027304240 @default.
• W1978768078 hasAuthorship W1978768078A5038774956 @default.
• W1978768078 hasAuthorship W1978768078A5044916391 @default.
• W1978768078 hasAuthorship W1978768078A5071439052 @default.
• W1978768078 hasAuthorship W1978768078A5079842256 @default.
• W1978768078 hasAuthorship W1978768078A5084542258 @default.
• W1978768078 hasAuthorship W1978768078A5086602129 @default.
• W1978768078 hasAuthorship W1978768078A5087699643 @default.
• W1978768078 hasBestOaLocation W19787680782 @default.
• W1978768078 hasConcept C112705442 @default.
• W1978768078 hasConcept C121608353 @default.
• W1978768078 hasConcept C126322002 @default.
• W1978768078 hasConcept C141071460 @default.
• W1978768078 hasConcept C197934379 @default.
• W1978768078 hasConcept C2776694085 @default.
• W1978768078 hasConcept C2777063308 @default.
• W1978768078 hasConcept C2777288759 @default.
• W1978768078 hasConcept C2777292972 @default.
• W1978768078 hasConcept C2778375690 @default.
• W1978768078 hasConcept C2778536324 @default.

• next